
Julio Arevalo-Perez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5402699/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	<scp>MRI</scp> Findings of Arachnoiditis, Revisited. Is Classification Possible?. Journal of Magnetic Resonance Imaging, 2021, 54, 904-909.	3.4	5
2	T1-weighted Dynamic Contrast-enhanced MRI to Differentiate Nonneoplastic and Malignant Vertebral Body Lesions in the Spine. Radiology, 2020, 297, 382-389.	7.3	18
3	Reliability of CT myelography versus MRI in the assessment of spinal epidural disease. Clinical Imaging, 2020, 62, 37-40.	1.5	1
4	Longâ€Term Outcome After Conventional Twoâ€Stage Hepatectomy Versus Tourniquetâ€ALPPS in Colorectal Liver Metastases: A Propensity Score Matching Analysis. World Journal of Surgery, 2019, 43, 2281-2289.	1.6	43
5	ALPPS for hepatocarcinoma under cirrhosis: a feasible alternative to portal vein embolization. Annals of Translational Medicine, 2019, 7, 691-691.	1.7	18
6	Differentiating Atypical Hemangiomas and Metastatic Vertebral Lesions: The Role of T1-Weighted Dynamic Contrast-Enhanced MRI. American Journal of Neuroradiology, 2018, 39, 968-973.	2.4	49
7	Calcifying pseudoneoplasm of the spine: imaging and pathological features. Neuroradiology Journal, 2018, 31, 440-444.	1.2	11
8	Diffusion Tensor Imaging Shows Corpus Callosum Differences between Highâ€Grade Cliomas and Metastases. Journal of Neuroimaging, 2018, 28, 199-205.	2.0	5
9	Tourniquet-ALPPS is a promising treatment for very large hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Oncotarget, 2018, 9, 28267-28280.	1.8	18
10	Diagnostic Accuracy of T1-Weighted Dynamic Contrast-Enhanced–MRI and DWI-ADC for Differentiation of Glioblastoma and Primary CNS Lymphoma. American Journal of Neuroradiology, 2017, 38, 485-491.	2.4	71
11	T1-Weighted Dynamic Contrast-Enhanced MR Perfusion Imaging Characterizes Tumor Response to Radiation Therapy in Chordoma. American Journal of Neuroradiology, 2017, 38, 2210-2216.	2.4	18
12	Dynamic Contrastâ€Enhanced MRI in Lowâ€Grade Versus Anaplastic Oligodendrogliomas. Journal of Neuroimaging, 2016, 26, 366-371.	2.0	25
13	Corpus Callosum Diffusion and Language Lateralization in Patients with Brain Tumors: A DTI and fMRI Study. Journal of Neuroimaging, 2016, 26, 224-231.	2.0	22
14	Comparison of Glioblastomas and Brain Metastases using Dynamic Contrastâ€Enhanced Perfusion MRI. Journal of Neuroimaging, 2016, 26, 240-246.	2.0	46
15	Early magnetic resonance imaging biomarkers to predict local control after high dose stereotactic body radiotherapy for patients with sarcoma spine metastases. Spine Journal, 2016, 16, 291-298.	1.3	32
16	Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients. Neuro-Oncology, 2016, 18, 735-743.	1.2	28
17	A Perspective of the Future of Nuclear Medicine Training and Certification. Seminars in Nuclear Medicine, 2016, 46, 88-96.	4.6	12
18	Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. Neuro-Oncology, 2016, 18, 283-290.	1.2	161

#	Article	IF	CITATIONS
19	Differentiating benign from malignant vertebral fractures using <i>T</i> ₁ â€weighted dynamic contrastâ€enhanced MRI. Journal of Magnetic Resonance Imaging, 2015, 42, 1039-1047.	3.4	23
20	Dynamic Contrastâ€Enhanced Perfusion MRI and Diffusionâ€Weighted Imaging in Grading of Gliomas. Journal of Neuroimaging, 2015, 25, 792-798.	2.0	66
21	Pre-operative fMRI localization of the supplementary motor area and its relationship with postoperative speech deficits. Neuroradiology Journal, 2015, 28, 281-288.	1.2	7
22	Parietal intradiploic encephalocele: Report of a case and review of the literature. Neuroradiology Journal, 2015, 28, 264-267.	1.2	10
23	T1-Weighted Dynamic Contrast-Enhanced MRI as a Noninvasive Biomarker of Epidermal Growth Factor Receptor vIII Status. American Journal of Neuroradiology, 2015, 36, 2256-2261.	2.4	46
24	Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma. Journal of Neuro-Oncology, 2015, 125, 183-190.	2.9	106
25	Cerebral toxoplasmosis in a patient with multiple myeloma. , 0, 13, 191.		Ο